All Articles
The median progression-free survival was 11.14 months with ivonescimab and 5.85 months with pembrolizumab (Hazard Ratio [HR], 0.51; 95% CI, 0.38-0.69; P NSCLC, and patients with brain metastases. Read More ›
Research United to CURE Follicular Lymphoma (FL) combines the shared mission and efforts of three leading blood cancer foundations to support and drive scientific innovation and accelerate clinical trials in FL. Read More ›
As patients search for financial options, medical practices, health systems, and patient advocacy organizations may want to increase diligence on options and referral opportunities that come to them offering to “help” patients. Read More ›
Metrics to Keep in Mind for Value-Based Cancer Care
Not all metrics are created equal. Read More ›
This new feature aims to provide ongoing lists of US-based phase 2 or 3 clinical trials that are actively recruiting, and it can be used to encourage patients to enroll in a clinical trial. This issues feature is focused on sarcoma. Read More ›
Once key practice indicators (KPIs) are selected, communicating the “what” and “why” to the team is important, and this piece offers some tips and tricks for
getting these KPIs out to the team. Read More ›
Leaders can best support change by realizing and then communicating to
the team that change is a process. Read More ›
The Centers for Medicare & Medicaid Services now covers the test based on the criteria established in its National Coverage Determination for blood-based CRC screening tests (NCD 210.3). The test is covered
once every 3 years for eligible Medicare beneficiaries. Read More ›
Medical practices that prescribe drugs for their patients have an ethical and legal liability to obtain drugs that meet safety, efficacy, and quality standards. Employers have a fiduciary responsibility to their employees to provide health benefit plans
that follow important US drug safety measures and help to ensure that counterfeit
and/or unsafe drugs are not provided to unsuspecting employees. Yet, some specialty pharmacies and vendors are offering international drugs to employee health
benefit plans. Read More ›
Various strategies to address cash flow problems in oncology practices are presented, such as tracking lapses in the revenue cycle, ensuring that the front office staff is collecting payments at the time of service whenever possible, and keeping a close eye on what has been charged on the practices credit card. Read More ›